Biotech | April 12, 2022
Cambrex completes large-scale US API expansion
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The expansion positions Cambrex with the largest and most advanced API facility in the United States
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
Essent continues to broaden its highly characterized, low passage primary cell catalog
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
The two-day event will showcase achievements and address issues pertaining to the industry
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Subscribe To Our Newsletter & Stay Updated
